Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. HOOD
8. DFTX
9. USO
10. MSFT

Go back to Protagonist Therapeutics (PTGX) Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera

Protagonist Therapeutics (PTGX) Misses Q1 EPS by 3c

May 7, 2020 5:40 PM EDT

Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of ($0.72), $0.03 worse than the analyst estimate of ($0.69).

"Based on the highly promising and consistent clinical responses achieved to date, we are pleased to... More